ImmuCell (ICCC) Q2 2025 earnings summary

Executive summary

• Product sales increased 18% year-over-year to $6.44M in Q2 2025 and 14% to $14.5M for the first half, driven by restored First Defense supply and improved production capacity.

• Net income reached $1.95M for the six months ended June 30, 2025, reversing a prior loss, with operating income swinging to $1.7M from a $1.7M loss.

• Gross margin improved to 44% in Q2 2025 (vs. 22% in Q2 2024) and 43% for the first half (vs. 28%), reflecting process improvements.

• Order backlog was eliminated and distributor inventory rebuilt by June 30, 2025, returning to normal sales channels.

• Initiated investigational use and field studies for Re-Tain®, with commercial launch pending FDA approval and other milestones.

Financial highlights

• Q2 2025 product sales were $6.44M, up 18% year-over-year; H1 2025 sales reached $14.5M, up 14% from H1 2024.

• Gross margin for Q2 2025 was 44%, up from 22% in Q2 2024; six-month gross margin was 43%, up from 28%.

• Net income for Q2 2025 was $502K ($0.06/share), compared to a net loss of $1.53M in Q2 2024.

• Adjusted EBITDA reached $1.4M (Q2), $3.7M (H1), and $5.3M (TTM) in 2025, up from negative values in 2024.

• Cash and cash equivalents increased to $6.0M as of June 30, 2025, from $3.8M at year-end 2024.

Outlook and guidance

• Inventory rebuild in H1 2025 provided a temporary sales boost; sales may soften in H2 2025 as distributor inventory normalizes.

• Management expects sufficient liquidity for at least the next 12 months, supported by improved cash flow and gross margin.

• Full commercial launch of Re-Tain® contingent on FDA approval, validated manufacturing, and sufficient cash.

• Management is exploring strategic options for Re-Tain® and expects to gather field performance data through early 2026.